Cargando…

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review

RATIONALE: The guidelines recommended gefitinib as a first-line targeted treatment for stage IV non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Yong, Li, Qijun, Miao, Qian, Li, Da
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238270/ https://www.ncbi.nlm.nih.gov/pubmed/34160440 http://dx.doi.org/10.1097/MD.0000000000026450

Ejemplares similares

Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
por: Chen, Mu-Tong, et al.
Publicado: (2023)

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis
por: Zhou, Jian-Guo, et al.
Publicado: (2015)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib
por: Aydiner, Adnan, et al.
Publicado: (2015)

Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807): An Open-Label, Single Arm, Multicenter Phase II Study
por: Zhao, Hong-Yun, et al.
Publicado: (2015)

Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer
por: Hisakane, Kakeru, et al.
Publicado: (2017)

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
por: Ma, Hu, et al.
Publicado: (2016)

S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report
por: Ohara, Sayaka, et al.
Publicado: (2014)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
por: Chen, Xiaofeng, et al.
Publicado: (2013)

Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report
por: Bie, Yanan, et al.
Publicado: (2021)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

Salvage radiochemotherapy for lymph node recurrence after radical surgery of esophageal cancer
por: Zhou, Yi-Qin, et al.
Publicado: (2018)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

High dose of nimustine as an add-on treatment for small cell lung cancer with intracranial metastasis: A case report and literature review
por: Luo, Wei, et al.
Publicado: (2017)

Successful treatment of 2 patients with brain metastases from non-small cell lung cancer with epidermal growth factor receptor mutation receiving dacomitinib: A case report
por: Zhao, Songchen, et al.
Publicado: (2021)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Predictors for survival in patients with bone metastasis of small cell lung cancer: A population-based study
por: Xue, MingFeng, et al.
Publicado: (2021)

Patterns of lymph node metastasis in locally advanced cervical cancer
por: Liu, Zhikai, et al.
Publicado: (2016)

Identification of novel biomarkers and small-molecule compounds for nasopharyngeal carcinoma with metastasis
por: Mi, Jing-Lin, et al.
Publicado: (2020)

Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review
por: Chen, Xiaoli, et al.
Publicado: (2023)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
por: Thomas, Preenumol, et al.
Publicado: (2019)

Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report
por: Jin, Yonglong, et al.
Publicado: (2021)

Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
por: Lee, Chia-Han, et al.
Publicado: (2022)

Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports
por: Lai, Lin, et al.
Publicado: (2021)

Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs
por: Li, Dailong, et al.
Publicado: (2022)

Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Zheng, Mao-hua, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vi2euvpnnunj945dnlvu78671p